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In recent years, DNA vaccines have undergone a number of technological advancements
that have incited renewed interest and heightened promise in the field.Two such improve-
ments are the use of genetically engineered cytokine adjuvants and plasmid delivery via
in vivo electroporation (EP), the latter of which has been shown to increase antigen delivery
by nearly 1000-fold compared to naked DNA plasmid delivery alone. Both strategies, either
separately or in combination, have been shown to augment cellular and humoral immune
responses in not only mice, but also in large animal models. These promising results, cou-
pled with recent clinical trials that have shown enhanced immune responses in humans,
highlight the bright prospects for DNA vaccines to address many human diseases.
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INTRODUCTION
Prevention is the most foolproof method of medical intervention,
and the vaccine is its most representative example. Since Edward
Jenner’s pioneering smallpox vaccine, vaccinology has followed an
irregular path to its modern day form, with alternating periods
of progress and stagnation (1, 2). Through advances in molecu-
lar biology, vaccinology has evolved from using basic inoculations
of whole microorganisms to harnessing the power and flexibil-
ity of genetic engineering (3). DNA vaccination, one of the latest
biotechnological breakthroughs, is the beginning of a new chapter
in vaccine technology.
The fundamental idea behind DNA vaccines (also known as
genetic vaccines) is to induce immune responses against recom-
binant antigens encoded by genetically engineered DNA plasmids
expressed in vivo. After immunization, host cellular machinery
facilitates the expression of plasmid-encoded genes, which leads
to the generation of foreign antigens that can be processed and
presented on both major histocompatibility complex (MHC) class
I and class II molecules. These host-synthesized foreign antigens
can be recognized by the immune system, inducing a complete
and effective immunization.
This novel method of vaccination was engineered in response
to a series of emerging diseases that remain without proper pro-
phylactic and therapeutic treatment. More than 50 years ago,
pioneering studies carried out by Atanasiu et al. and Orth et al.
showed that inoculation of mouse-derived tumor DNA induced
tumors and led to seroconversion in injected mice (4, 5). The
work of Wolff et al. showed that DNA plasmids injected intramus-
cularly (i.m.) could generate long-term gene expression in vivo
without the need for a special delivery system (6); this finding
helped generate much excitement for the scientific community.
Within the past decade, four successful DNA plasmid products
have been licensed for animal use: one for the treatment of West
Nile virus in horses (7), one against hematopoietic necrosis virus
in salmon (8), one for the treatment of melanoma in dogs (9),
and a growth hormone-releasing hormone (GHRH) gene therapy
for swine (10). However, despite promising studies in small ani-
mal models and improved efficacy in large animal models, the
clinical ability of DNA vaccines still remains unproven. While
the reasons for this inconsistency have yet to be fully elucidated,
several attempts have been made to enhance immunogenicity in
humans, resulting in studies that have provided a wealth of con-
structive information that may guide research efforts toward the
development of improved DNA products.
This review will focus on specific combined DNA vaccine
approaches to improving immunogenicity in humans. In par-
ticular, we highlight in vivo electroporation (EP) and the use of
genetically encoded immune adjuvants. These important techno-
logical advancements have helped drive the field of DNA vaccines
into a modern resurgence, and the use of these techniques –
along with improved protocols and methods for synthetic gene
production – may be the key to successfully controlling a number
of human diseases.
BEGINNINGS OF DNA VACCINATION
The seeds of DNA vaccinology were planted in the mid-twentieth
century, when studies by Stasney et al. (11), Paschkis et al. (12), and
Ito (13) demonstrated the ability to transfer DNA to animal cells
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by injection of crude DNA preparations isolated from tumors.
These reports and others laid the groundwork for DNA vac-
cines by showing that DNA injection into animals can result
in the expression of the delivered genes in vivo. However, per-
haps the most important aspect of these early studies was that
the immune system could respond to the gene products gen-
erated by DNA inoculation. For example, Atanasiu et al. (4)
and Orth et al. (5) purified DNA extracts from polyoma viruses
and demonstrated both tumor induction and the generation of
anti-polyoma antibodies in injected animals. These findings were
extended in studies by Israel and colleagues, who observed that
injection of recombinant purified polyoma virus DNA resulted in
tumor formation and anti-polyoma antibody production (14).
Will and coworkers also observed humoral immune responses
after inoculation of recombinant purified hepatitis B viral DNA
into chimpanzees (15).
While many of these initial studies primarily focused on study-
ing viral DNA biology (with humoral immunity against the inoc-
ulated gene product being of secondary importance), later studies
sought to specifically study plasmid gene expression in vivo for
a variety of applications. For example, Benvenisty and Reshef
delivered genes encoding insulin and human growth hormone
(HGH) into newborn rats, resulting in their expression in vivo
(16). Later, studies by Jon Wolff and colleagues demonstrated long-
term expression of DNA plasmids injected intramuscularly in mice
(6). And in 1992, Tang et al. directly studied the immune response
in mice elicited by DNA inoculation of foreign proteins. Using a
gene gun to shoot gold particles coated with HGH-encoding DNA
into mouse skin, the researchers found detectable levels of anti-
bodies against the hormone, thus reproducing the earlier work of
Israel, Atanasiu and Orth but in a more controlled manner (17).
At the annual Cold Spring Harbor Vaccine meeting in September
1992, the laboratories of Margaret Liu (Merck), Harriet Robinson
(University of Massachusetts), and David Weiner (University of
Pennsylvania) independently reported that plasmid delivery into
small animals could induce antibodies and cytotoxic T lympho-
cytes (CTLs) against influenza virus (18, 19) or HIV (20). Together,
these studies were instrumental in laying the groundwork for the
DNA vaccine field.
To date, three DNA vaccines and one DNA-based hormone
therapy have been licensed for veterinary use, illustrating the
advancements in DNA plasmid technology that have allowed these
products to be successful in animals both big and small. A DNA
vaccine for West Nile Virus in horses, licensed in 2005, was first
shown to be efficacious in mice and horses before licensure (7).
After licensure, the vaccine entered phase 1 clinical trials and was
shown to induce neutralizing antibodies in healthy adults (21, 22).
Also licensed in 2005, the infectious hematopoietic necrosis virus
vaccine targets school salmon and has resulted in improved food
quality and quantity (8, 23, 24). The canine melanoma vaccine,
fully licensed in 2010 after conditional licensing in 2007, encodes
human tyrosinase, allowing the immune system to break tolerance
to canine tyrosinase and generate an effective immune response
against tumor cells (9, 25). Another groundbreaking use of DNA
plasmids that received licensure in 2007 was the GHRH product
for use in swine (10). As the first licensed EP-delivered product
and the first licensed gene therapy product, DNA-encoded GHRH,
which causes an increase in growth hormone, has allowed more
piglets to be weaned by improving maternal performance (26). All
of these breakthroughs, some of which have taken place in animals
larger than humans, have validated the very real potential of DNA
product licensure for human use.
DNA VACCINE MECHANISM: HOW DOES IT WORK?
DNA vaccination is an attractive immunization platform due to its
ability to elicit potent CTL responses while preserving the capac-
ity to stimulate other arms of the immune system. DNA vaccines
achieve this goal by mimicking aspects of natural viral infections:
the expression of foreign genes delivered in vivo results in the
production of proteins that are processed and presented to the
immune system quite similarly to proteins encoded by viral genes.
The end result of DNA vaccination is the production of non-live,
non-replicating, non-spreading antigens that can induce not only
CD4+ and CD8+ T-cell immunity, but also B-cell immunity. The
details of the mechanisms by which some components of DNA
vaccination are achieved is still under investigation. Nonetheless,
many of the key steps of DNA immunization have been partially
elucidated.
Two major cell types are required for initiating the immune
response elicited by DNA vaccination: somatic cells (primarily
myocytes or keratinocytes) and professional antigen-presenting
cells (APCs). For example, after intramuscular injection of a plas-
mid, myocytes, resident dendritic cells (DCs), and monocytes are
transfected (27–30). Upon entering the nucleus of transfected
cells, the plasmid-encoded genes are expressed, and foreign anti-
gens are generated and processed into peptide strings by host
cell machinery. These peptides can then be associated with the
MHC class I or II molecules of APCs, affording these cells the
ability to prime naïve T cells in the draining lymph nodes. While
direct transfection of DCs is one method in which vaccine-derived
endogenous peptides can form complexes with MHC class I mol-
ecules and prime naïve CD8+ T cells, DCs may also cross-present
cell-associated exogenous antigen obtained from engulfing apop-
totic or necrotic transfected cells (31, 32). DCs may also display
peptides via MHC class II molecules by capturing antigen secreted
from transfected cells. Ultimately, plasmid products are capable of
accessing both pathways, resembling many aspects of viral protein
immune induction.
ADVANTAGES OF DNA VACCINES
Since its inception, there has been great promise in DNA vaccina-
tion. Using genetic material as a vector for immunization offers a
number of advantages over traditional vaccine modalities in terms
of effectiveness, safety, and cost. For years, scientists have put great
effort into maximizing these strengths in order to establish DNA
vaccines as a central component of preventative and therapeutic
medicine.
IMMUNOLOGICAL ADVANTAGES
The main advantage of DNA vaccines is their ability to stimu-
late both the humoral and cellular arms of the adaptive immune
system. In regards to humoral immunity, the generation of anti-
bodies by B lymphocytes against invading pathogens is one of the
most effective defenses mounted by the immune system. Vaccines
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that utilize live-attenuated microorganisms, killed viral particles,
or recombinant viral proteins elicit the production of specific anti-
bodies that bind superficial microbial structures on the target
pathogen. Unfortunately, immunological pressure or imprecise
genome replication can cause certain pathogens to accumulate
mutations that reduces the effectiveness of antibodies originally
generated against the pathogen. Typically, antibody responses gen-
erated by traditional vaccines target only the specific antigens
found in the inoculum, and are poorly able to control similar
pathogens that carry either subtle or gross changes to the antigen.
Due to the ability to genetically modify the antigen encoded by
DNA vaccines, the vaccine can be designed to contain the most
highly conserved regions of the superficial, antibody-generating
structures on a pathogen, providing a means to generate broadly
neutralizing antibodies against pathogens such as HIV and the
influenza virus.
Regarding cellular immunity, CTLs eradicate infected or malig-
nant cells upon recognition of foreign antigens in complex with
MHC class I molecules on the target cell. Live-attenuated microor-
ganisms can enter cells, and their viral proteins can be processed
and directed to the MHC class I pathway for presentation upon
the cell surface and the subsequent induction of CTL-mediated
adaptive immunity. DNA vaccines also enter cells and produce
antigen that can be processed and presented via MHC class I;
however, DNA vaccines eschew the reversion risks associated with
live-attenuated microorganisms.
Another major advantage of the DNA vaccine model is its ver-
satility. In addition to the prevention of infectious diseases, DNA
vaccines may also be used to treat malignancies and autoimmune
or genetic disorders. When used for cancer therapy, plasmid DNA
encoding a tumor-associated antigen (TAA) can be designed to
induce CTL responses against cancerous cells expressing the anti-
gen (33). Concerning autoimmune disorders, DNA plasmids may
encode immunomodulatory proteins that could tailor the immune
response to the type and intensity needed to ameliorate conditions
as common as juvenile diabetes or food allergies.
SAFETY ADVANTAGES
Vaccines as a whole have maintained a very strong safety pro-
file. Nevertheless, live-attenuated and inactivated pathogens used
in traditional vaccines carry the potential to return to virulence,
which may cause pathogenic infections in vivo (34, 35), partic-
ularly in immunocompromised individuals. DNA vaccines, on
the other hand, do not use microorganisms and therefore avoid
the risk of reversion. Additionally, frequent vaccine-induced side
effects such as headache, fever, and transient pain have shown
reduced rates with DNA vaccines (36). Investigations into the
possibility of DNA vaccine plasmids integrating into the host chro-
mosome have not shown relevant levels of integration to occur (37,
38). Furthermore, preclinical and clinical studies have not detected
detrimental anti-vector autoimmunity (i.e., disease-causing anti-
nuclear or anti-DNA antibodies) after DNA vaccination, making
it possible to administer multiple doses of DNA vaccines without
triggering an immune reaction to the plasmid vector (39, 40); such
an immunization protocol may be particularly useful for therapeu-
tic cancer vaccination, which relies on repeated boosting of T-cell
responses to be effective. This is in contrast with viral or bacterial
vectors, which often induce anti-vector immunity that prevents
boosting with the same vector (41). Lastly, while there has been
evidence of anti-DNA antibodies generated as a result of epitope
spreading (42), these antibodies were found to be transient and,
most importantly, purely innocuous in animal models (43).
DNA VACCINE ENHANCEMENTS: IMPROVING
IMMUNOGENICITY
DNA CONSTRUCT OPTIMIZATION
Early in the development of DNA vaccines, it became clear that
maximizing the expression and synthesis of the encoded antigen
was vital to the induction of strong and potentially protective
immune responses. Bolstered by technological advancements in
the DNA vaccine field, the relative simplicity of naked plasmid
DNA has gradually given rise to a series of more sophisticated
products that confer higher levels of immunogenicity to DNA
vaccines.
Eukaryotic promoters, for instance, are no longer used, and
most DNA vaccines now rely on a strong viral promoter for opti-
mal transgene expression levels. Popular promoters taken from
human oncogenic viruses such as simian virus 40 (SV40) (44)
or Rous sarcoma virus (RSV) (45) have been replaced by effective
non-carcinogenic alternatives: the human cytomegalovirus imme-
diate early promoter (hCMV-IE) (46) and the CMV-chicken-β-
actin (CAG) promoter have been shown to induce high consti-
tutive expression in a wide range of mammalian cells (47), and
are now the most widely used promoters in current preclinical
studies and clinical trials. However, the choice of a promoter is
still a delicate matter; some studies have demonstrated that the
inherent strength of viral promoters does not necessarily correlate
with DNA vaccine efficacy in vivo, partly due to various cytokines
attenuating viral promoter activity (48). IFN-γ, one of the pri-
mary proteins responsible for this effect, is secreted to inhibit the
propagation of viruses by inducing transcriptional repressors that
downregulate viral replication (49). Consequently, both cellular
(50, 51) and hybrid (52) promoters are currently being tested as
possible alternatives to viral promoters. The human MHC class II
promoter has been shown to be a weak but interesting alternative,
particularly because the protein controlling its expression – the
MHC class II transactivator (CIITA) – is upregulated by antiviral
cytokines (53).
In addition to viral promoters, transcriptional transactivators
and other enhancer elements can also increase transcription activ-
ity. Most of the transactivator genes that have been evaluated thus
far have viral origins, such as the regulatory R region from the 5′
long terminal repeat (LTR) of human T-cell leukemia virus type
1 (HTLV-1). This particular element, combined with a CMV pro-
moter, has been shown to induce a suggestively higher cellular
immune response to HIV-1 compared to the analogous parental
DNA vaccines in both mice and non-human primates (54).
Despite promising results, the use of such regulatory enhancers
is of some concern for off target effects and will need additional
investigation.
Improving vaccine potency by optimizing translation efficiency
is also an active area of research. The insertion of a Kozak sequence
flanking the AUG initiator codon (ACCAUGG) within mRNA
may facilitate its recognition by eukaryotic ribosomes (55). Several
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studies have demonstrated that the presence of a Kozak sequence
adjacent to the start codon has a positive influence on gene expres-
sion from DNA plasmids (55, 56). Moreover, proper termination
is as important as proper initiation; double stop-codons can be
added to prevent read through, which could lead to oversized
and/or misfolded proteins (57).
Codon optimization is another common and highly efficient
technique used to enhance protein production (58). Not all organ-
isms use certain codons equally; this is due to variable levels of
transfer RNAs (tRNAs) within cells, resulting in a usage preference
for certain codons between species. As a result, unmodified bac-
terial or viral genes may not be optimally translated in eukaryotic
cells. Therefore, designing DNA plasmid constructs in which the
codon usage is optimized for eukaryotic cells may lead to more
efficient translation, resulting in enhanced protein production
(59). Consequently, augmented antigen expression can enhance
both humoral and cellular responses (59–66). By using similar
technology, it is also possible to add sequences that improve sta-
bility and thus translation of mRNA, such as leader sequences
and polyadenylation signal sites; conversely, removing elements
that decrease stability – such as secondary mRNA structures that
inhibit ribosomal loading or cryptic sequences that inhibit mRNA
nuclear export – can also improve mRNA stability and translation.
Lastly, there are modifications that do not directly affect the
transcription or translation, but instead cause changes in the con-
stitution or destination of the final protein. Protein modifications
that enable cell surface expression or secretion (e.g., inclusion of
secretion signal sequences) are commonly linked with augmented
immunogenicity (67, 68). Targeting the expressed protein to spe-
cific intracellular pathways such as the proteasomal pathway may
also increase MHC class I-restricted presentation. Additionally,
current technology offers the possibility of finding conserved and
common sequences among different pathogens (also called con-
sensus sequences). Using these sequences as transgenes for immu-
nization may maximize protection against multiple and highly
variable pathogens (68–70).
ELECTROPORATION
Of the many advancements in DNA vaccines that have drasti-
cally improved immunogenicity, plasmid delivery via in vivo EP
has proven to be one of the more impactful enhancements. EP
involves the application of brief electric pulses to the vaccination
site after injection of plasmid DNA. Administering EP results in
the formation of transient pores in the plasma membrane of cells
at the injection site (71, 72), which allows macromolecules such as
nucleic acids to enter the cytoplasm (73). While the mechanisms
for plasmid delivery by EP are still incompletely understood, the
procedure improves plasmid delivery by a factor of 10–1,000 fold
over naked DNA delivery alone (74). After the cessation of the
electric pulses, pore closure traps the macromolecules within the
cytoplasm. Not only does EP mediate enhanced plasmid uptake,
but it also increases DNA distribution throughout the tissue and
causes a local inflammatory reaction, both of which contribute to a
stronger immune response (75). Importantly, the safety profile of
EP after DNA vaccination is very similar to that of DNA delivered
without EP, with no increased risk of toxicity or integration of the
DNA plasmid into transfected cells. The most common adverse
event described in clinical trials involving DNA vaccination with
EP was increased pain at the application site.
While directly translating enhanced plasmid delivery to
improved gene expression and immune responses is not without
difficulty, comparison studies using reporter gene systems or
immunogenicity readouts have established a strong correlation
between EP delivery and augmented gene expression and immune
responses (Figure 1) (30, 76, 77). Furthermore, these improve-
ments in DNA vaccine expression and potency can be achieved
at significantly lower doses than with naked DNA delivery alone.
A number of preclinical studies in small and large animal models
have generated a substantial profile on the application of EP with
DNA vaccination. For example, administration of the HIV DNA
vaccine ADVAX was shown to increase antigen-specific CD4+ and
CD8+ T-cell responses in mice when delivered by EP (78). Addi-
tional preclinical studies in pigs (79), cows (80, 81), rabbits (82),
and others have had similar positive results in their respective DNA
vaccine models with EP. A recent study compared protective anti-
body responses in chickens given a DNA vaccine containing the
hemagglutinin (HA) gene of the avian influenza H5N1 virus deliv-
ered with or without EP (83): of the chickens that had the vaccine
delivered by EP, 100% showed complete protection (low viral load
and absence of clinical symptoms and mortality), while only 20%
of the chickens who received the vaccine without EP developed
antibodies.
However, the largest impact of EP on DNA vaccination has
come from its promising effects in large animals such as non-
human primates. When an optimized, synthetically developed SIV
DNA vaccine was delivered by adaptive EP to rhesus macaques,
the vaccine induced a greater magnitude of IFNγ-producing cells,
greater proliferative capacity of CD8+ T cells, and increased poly-
functionality of CD4+ and CD8+ T cells compared to the Merck
adenovirus serotype 5 (Ad5) SIV vaccine (84). This important
study showed that DNA vaccines had indeed made long strides
toward improving immunogenicity in large animals, surpassing
FIGURE 1 | Delivery of DNA vaccine with in vivo electroporation
enhances cellular immune responses. A DNA vaccine encoding HIV-1
consensus immunogens was injected intramuscularly with or without EP
into rhesus macaques. Interferon (IFN) gamma ELISpots were performed
2 weeks after the third (final) immunization; total antigen-specific cellular
responses are shown, n=5 per group. ELISpot, enzyme-linked
immunospot assay; HIV-1, human immunodeficiency virus-1; SFU,
spot-forming units; PBMCs, peripheral blood mononuclear cells; IM,
intramuscular injection; IL, interleukin. Modified from Hirao et al. (77).
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the potency of the live vector Ad5. Numerous studies in non-
human primates – using DNA vaccines for diseases such as anthrax
(85), monkeypox (86), and malaria (87, 88) – have further empha-
sized the impact of EP on drastically enhancing immunogenicity
in large animals.
The augmented immunogenicity observed in preclinical stud-
ies has also carried over to clinical trials. Recent results from a
human papillomavirus (HPV) 16/18 DNA vaccine phase I trial
have shown that vaccination with adaptive EP induced HPV-
specific CD8+ T cells that exhibited robust cytolytic functionality
(89). Furthermore, almost all the vaccinated women in this study
seroconverted with high titer to the antigens in the vaccine. The
immune response induced by the DNA vaccine was superior to
both viral and non-viral vaccines previously tested by others in
the same disease model (90–94). In a phase I trial of a therapeu-
tic approach for an HIV DNA vaccine ADVAX, static EP delivery
of the vaccine elicited an improved HIV-specific cell-mediated
immune response compared to vaccination without EP (95). How-
ever, there was no difference in antibody levels between the two
delivery methods. Furthermore, DNA vaccination with EP delivery
has been shown to induce humoral responses following adminis-
tration of a prostate cancer DNA vaccine with EP (96). These
results illustrate the immense progress DNA vaccination has made
over the past decade, with the induction of strong responses that
may prove beneficial against the diseases targeted.
As with any technology in its early stages of development, addi-
tional work needs to be done to optimize EP in order to modulate
the immunogenicity of DNA vaccines and reduce the associated
side effects – namely, the pain generated at the application site.
Alteration of the pulse patterns, electrode configurations, imped-
ance of target tissues, and additional factors all can influence the
immune response elicited by the DNA vaccine. By employing dif-
ferent types of electrodes, EP can be compatible with both i.m.
and i.d. delivered DNA vaccines (76, 97–100) and can also be used
in conjunction with chemical formulations or other mechanical
approaches for better results. For example, in vivo EP of porcine
skin after injection of plasmid in combination with aurintricar-
boxylic acid (ATA) was shown to increase transgene expression
∼115-fold relative to plasmid injection alone, 2- to 3-fold over
DNA with EP, and 17-fold over DNA combined with ATA (101).
In the same manner, a microneedle array with electrical function-
ality has shown encouraging results in human epidermal cells as
well as human red blood cells (102). Recent optimizations to a
minimally invasive surface intradermal EP device have shown that
low-voltage EP applied to the skin can elicit robust humoral and
cellular immune responses without tissue damage (103). Some of
these changes to the EP protocol may be broadly applicable to
a number of different DNA vaccines, while other DNA vaccines
will require specialized tweaks to the EP protocol to generate the
precise immune response needed to combat the intended target.
GENETIC ENHANCING STRATEGIES: ADJUVANTS
Because low immunogenicity has been the major deterrent
toward using DNA vaccines in large animals and humans, sev-
eral approaches have been investigated to increase the intensity
and duration of vaccine-induced immune responses. One popu-
lar strategy has been to create vaccine cocktails, which includes the
DNA vaccine along with plasmids encoding immunomodulatory
proteins. Such adjuvant-encoding genes can be delivered either as
separate plasmids or as additional genes encoded by the antigen-
encoding plasmid. Upon vaccination, cells transfected with the
adjuvant-encoding plasmid can express and secrete the molec-
ular adjuvant into the surrounding region, affecting local APCs
and cells in the draining lymph node. The end result is long-
lasting, low level production of immunomodulatory cytokines
that can tailor the immune response to the demands of each par-
ticular pathogen. For example, protection from certain viruses,
other intracellular pathogens, or tumors may benefit from the use
of cytokines that induce Th1-type immunity, such as IL-2, IL-
12, IL-18, and IFNγ, which all generally promote cell-mediated
immune responses (104). Conversely, cytokines such as IL-4 and
IL-5 may be useful against extracellular pathogens while IL-10 and
transforming growth factor-β (TGFβ) may prove effective in treat-
ing autoimmune disorders that arise from aberrant cell-mediated
immunity (104). And while the role of Th17 cells during infec-
tion varies from pathogen to pathogen, evidence suggests that this
cell subtype assists in the resistance to a number of bacterial and
parasitic infections such as Leishmania (105, 106), Pseudomonas
aeruginosa (107), Mycobacterium tuberculosis (108), and others.
Cytokines such as TGFβ and either IL-6 or IL-21 are required for
Th17 differentiation and may be useful for directing a Th17-type
immune response during vaccination. By raising the concentration
of certain immunomodulatory proteins during the initiation or
boosting of an immune response, one can selectively activate or
inhibit the division of the immune system that would lead to the
greatest immunological benefit.
Another adjuvant strategy involves using plasmids encoding
cytokines capable of recruiting, activating, and/or enhancing the
activity of APCs. Granulocyte-macrophage colony-stimulating
factor (GM-CSF), a white blood cell growth factor, is perhaps the
best characterized example of this adjuvant approach. Plasmid-
encoded GM-CSF, when used in combination with a rabies
virus DNA vaccine, was shown in mice to increase CD4+ T-
cell responses, antibody production, and protection from lethal
challenge (109). Similarly promising results have been seen in
murine models of HIV (110, 111), herpes simplex virus-2 (HSV-
2) (112), encephalomyocarditis virus (113), and hepatitis C virus
(114). Unfortunately, these results were not recapitulated in clin-
ical trials, allegedly due to a relative lack of GM-CSF receptors
on human APCs compared to their murine counterparts (115).
Nonetheless, other cytokines are currently being studied as can-
didate DNA vaccine adjuvants. CXC chemokines such as IL-8
(116), as well as CC chemokines such as macrophage inflamma-
tory protein (MIP)-1α (117, 118), MIP-3α (118), MIP-3β (119),
and RANTES (120), may increase the potency of the immune
response. Ultimately, these proteins can augment vaccine-induced
immune responses by coordinating the movement and functional-
ity of leukocytes important for antigen presentation; this suggests
that the immunogenicity of DNA vaccines may be limited by the
availability of APCs at the site of inoculation.
DNA vaccine immunogenicity can also be enhanced by co-
delivering plasmid-encoded co-stimulatory and adhesion mol-
ecules. For example, administration of B7-1 (CD80) and B7-2
(CD86), proteins that provide the crucial second signal required
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for T-cell activation (121, 122), has been shown to increase CTL
activity in cancer and HIV, respectively (123–125). Additionally,
blockade of co-inhibitory molecules has been another strategy
employed in recent DNA vaccination research. For example, block-
ing interactions between the co-inhibitory receptor programed
death 1 (PD-1) on T cells with its ligands PD-L1 or PD-L2 has been
shown to prevent negative regulation of T-cell responses during
chronic viral infection and cancer (126). Plasmid-encoded soluble
PD-1, when used in combination with either HPV (127) or HIV
(128) DNA vaccines, was found to increase antigen-specific CD8+
T-cell responses compared to the vaccine alone in mice. In the case
of adhesion molecules, interactions between the ligands LFA-3 and
ICAM-1 (expressed on APCs) and their corresponding receptors
CD2 and LFA1, respectively (expressed on T cells) facilitate the for-
mation of a stable cellular synapse and contribute to optimal sig-
naling between cells. Kim et al. demonstrated that the co-injection
of the genes for these adhesion molecules – particularly LFA-3 –
together with plasmid DNA leads to an increase in antigen-specific
lymphoproliferative and cytotoxic responses (111). Importantly,
while the options for gene-based immunomodulatory proteins
are almost overwhelmingly numerous, the real challenge resides
in finding the combination and timing suitable for each adjuvant
that will lead to protective results in clinical trials.
INTERLEUKIN-12
One particular cytokine that has received extensive attention in
the DNA vaccine field is interleukin-12 (IL-12). IL-12 plays a key
role in adaptive immunity as a driving force in T-helper cell type
1 immunity; as such, it has been shown to stimulate the pro-
duction of IFNγ by T cells and augment CD8+ cytotoxic T-cell
activity (129). As one of the earliest Th1-specific cytokine genetic
adjuvants explored (130), work from our laboratory and collabo-
rators have revealed the strong activity of IL-12 as a DNA vaccine
adjuvant (Figure 2). For example, co-delivery of plasmid IL-12
increases the activation, proliferation, and effector function of T
FIGURE 2 | Co-administration of DNA vaccine with plasmid IL-12
increases cellular immune responses. A DNA vaccine encoding HIV-1
consensus immunogens was administered intramuscularly (without EP) to
rhesus macaques with or without plasmid-encoded IL-12. Interferon (IFN)
gamma ELISpots were performed 2 weeks after the third (final)
immunization; total antigen-specific cellular responses are shown. n= 5 per
group; ***represents p<0.001. ELISpot, enzyme-linked immunospot
assay; HIV-1, human immunodeficiency virus-1; SFU, spot-forming units; IL,
interleukin. Modified from Hirao et al. (77).
cells in NHP (131, 132). This increase in functional T cells includes
a 22-fold improvement in CTL responses and enhanced protection
in a macaque challenge model. Additional studies in large animals
have further highlighted the strong adjuvant effects of plasmid IL-
12 (133–137). Additionally, delivering an HIV DNA vaccine with
plasmid IL-12 by EP in macaques resulted in an integrative increase
in the magnitude and proliferative capacity of antigen-specific
IFNγ-producing cells compared to i.m. DNA immunization alone
(77). Preclinical studies in other disease models such as hepatitis
C (138), HSV-2 (139), and Toxoplasma gondii infection (140) fur-
ther illustrate why plasmid-encoded IL-12 is a fantastic molecular
adjuvant for DNA vaccination.
These important preclinical studies have led to exploring IL-12
as a genetic adjuvant in human clinical trials. First-in-human syn-
thetic HIV DNA vaccine trials in combination with IL-12 plasmid
showed a higher percentage of vaccinated individuals developing
a detectable cellular immune response compared to those who
received the HIV DNA vaccine alone (137). Combining this vac-
cine regimen with in vivo EP dramatically amplified these results
[(141); JID], showing that the inclusion of cytokine gene adjuvants
with EP can improve adjuvant effects. More specifically, plasmid
IL-12 and EP are capable of generating positive effects both in large
animal models and in humans. Expanded studies of this important
combination are in progress.
CONCLUSION
The early promise of DNA vaccination had been tempered by
lackluster immune responses in large animal models and humans.
However, technological advances in the last decade have gener-
ated renewed interest in the improved, synthetically designed,
and newly formulated DNA vaccine, especially when delivered by
enhanced EP systems. Improved plasmid delivery via in vivo adap-
tive EP and the use of genetic adjuvants (in particular as plasmid-
encoded IL-12) have proven to be powerful enhancers of DNA vac-
cines. Not only have these strategies improved immune responses
in a variety of preclinical vaccination studies, but increasing
evidence is suggesting that these approaches can also augment
immune responses in humans. Given the various advantages of
DNA vaccines – their ease of design, strong safety record, and sta-
bility, amongst others – the enhancements in immune responses
in large animal models and humans is incredibly encouraging for
the viability of DNA vaccines as a competitive vaccine platform. To
carry these promising results further, additional research is needed
on novel adjuvants, the timing of adjuvant administration, and the
combination of genetic adjuvants and EP for optimal vaccination
protocols. The prospects for treatment and prevention of human
and animal disease by DNA vaccines are exciting, and the contin-
ual refinement of these technologies bode well for the present and
future of this vaccine field.
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